Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 6/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 3/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL445084 | 0.94 | POLB (0.47) | POLBTDP1GAASMN1; SMN2TSHR | |
| Benzoic Acid SCHEMBL6049039 | 0.86 | TDP1 (0.62) | POLBTDP1GAASMN1; SMN2TSHR | |
| SCHEMBL18668123 | 0.83 | SMN1; SMN2 (0.51) | POLBTDP1GAASMN1; SMN2KMT2A | |
| SCHEMBL16521477 | 0.79 | KMO (0.58) | TSHRALDH1A1MAPTHTT | |
| SCHEMBL8775309 | 0.79 | KMO (0.58) | TSHRALDH1A1MAPTHTT | |
| SCHEMBL11374054 | 0.79 | KMO (0.58) | TSHRALDH1A1MAPTHTT | |
| SCHEMBL7000719 | 0.79 | AKR1C3 (0.45) | POLBTDP1GAASMN1; SMN2TSHR | |
| SCHEMBL10739512 | 0.78 | POLB (0.54) | POLBTDP1GAASMN1; SMN2TSHR | |
| SCHEMBL31737192 | 0.78 | POLB (0.54) | POLBTDP1GAASMN1; SMN2TSHR | |
| SCHEMBL10739509 | 0.78 | POLB (0.54) | POLBTDP1GAASMN1; SMN2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9199934-B2 | Alpha-hydroxyketones | BASF SE (DE) | 2015-12-01 | — | — | US | disclosed |
| EP-2129659-B1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2013-05-29 | — | — | EP | disclosed |
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | IGM GROUP B.V. (NL) | 2010-04-29 | — | — | US | disclosed |
| EP-2129659-A1 | ALPHA-HYDROXYKETONES | BASF SE (DE) | 2009-12-09 | — | — | EP | disclosed |
| WO-2008122504-A1 | ALPHA-HYDROXYKETONES | BASF SE (CH) | 2008-10-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100104979-A1 | ALPHA-HYDROXYKETONES | C9, C1R, CBR3 | POLB 2943/4885TDP1 4511/4885GAA 4240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.